Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma - PubMed (original) (raw)
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma
Robert J Rounbehler et al. Cancer Res. 2009.
Abstract
Neuroblastoma is a pediatric malignancy that arises from the neural crest, and patients with high-risk neuroblastoma, which typically harbor amplifications of MYCN, have an extremely poor prognosis. The tyrosine hydroxylase (TH) promoter-driven TH-MYCN transgenic mouse model faithfully recapitulates many hallmarks of human MYCN-amplified neuroblastoma. A key downstream target of Myc oncoproteins in tumorigenesis is ornithine decarboxylase (Odc), the rate-limiting enzyme of polyamine biosynthesis. Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc. Here, we report that DFMO treatment, but not Odc heterozygosity, impairs MYCN-induced neuroblastoma and that, in this malignancy, transient DFMO treatment is sufficient to confer protection. The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins. These findings suggest that agents, such as DFMO, that target the polyamine pathway may show efficacy in high-risk, MYCN-amplified neuroblastoma.
Figures
Figure 1
Pediatric neuroblastoma with MYCN amplification express elevated levels of ornithine decarboxylase (ODC). A, Hierarchical clustering of _MYCN_-amplified and non-amplified 101 primary human neuroblastoma samples from Gene Expression Omnibus Series GSE3960. This clustering differentiated _MYCN_-expressing and non-expressing tumors. Genes within the polyamine pathway present in the Affymetrix microarray data are shown. Genes that are marked with an asterisk (*) are significantly different (p<0.05) between the _MYCN_-amplified and non-_MYCN_-amplified groups. B, Real-Time PCR analysis comparing the mRNA expression of MYCN and polyamine pathway genes ODC and SMS in human neuroblastoma cell lines SK-N-MC, SK-N-SH, IMR-32, and CHP-134. The relative expression level of each gene is set at 1.0 for the SK-N-MC cell line and levels of mRNA are standardized to the expression of ubiquitin, which is not regulated by Myc oncoproteins. Standard error bars are provided for each cell line. The qRT-PCR analysis for other polyamine genes is provided in Supplementary Fig. S2. C, Western blot analysis of MYCN, ODC, and Actin in human neuroblastoma cell lines SK-N-MC, SK-N-SH, IMR-32, and CHP-134.
Figure 2
DFMO selectively impairs the proliferation of _MYCN_-amplified human neuroblastoma. A, The change in cell cycle distribution of the human neuroblastoma cell lines SK-N-MC, SK-N-SH, IMR-32, and CHP-134 upon DFMO treatment for 72 hours is shown. Cells were labeled with BrdU, harvested, and analyzed by FACS. The graph represents the difference in the average of two mock-treated samples and two DFMO-treated samples for each cell line (see also Supplementary Fig. S3). B, Human neuroblastoma cell lines SK-N-MC, SK-N-SH, IMR-32, and CHP-134 were either mock-treated (solid line) or were treated with DFMO (5 mM, dashed lines) and cell number was determined daily. The graph shown represents the average cell count relative for three mock-treated samples and three DFMO-treated samples from each cell line. Standard error bars are provided.
Figure 3
DFMO-treatment suppresses neuroblastoma development in TH-MYCN transgenic mice. A, Survival curve of TH-MYCN transgenic mice untreated (H2O), DFMO-treated, or DFMO-treated from weaning until 120 days of age. The blue arrow above the graph indicates the time (120 days of age) when a cohort of DFMO-treated mice was taken off the drug. Comparison of the survival curves by the Mantel-Cox Log-rank Test shows that the curves are significantly different (p=0.0050). B, Survival Curve of TH-MYCN;Odc+/+ mice versus TH-MYCN;Odc+/- littermates. Comparison of the survival curves by the Mantel-Cox Log-rank Test shows that the curves are not significantly different (p=0.6241).
Figure 4
DFMO-induced growth arrest of _MYCN_-amplified neuroblastoma is associated with the selective induction of p21Cip1. A, qRT-PCR analysis comparing the ODC, p21CIP1, and p27KIP1 mRNA levels of in human neuroblastoma cell lines SK-N-MC, SK-N-SH, IMR-32, and CHP-134 following DFMO treatment for 72 hr. The graph represents the average relative expression for two mock-treated samples and two DFMO-treated samples from each cell line. The relative expression level of each gene is set at 1.0 for the mock-treated samples of each cell line and levels of mRNA are standardized to the expression of ubiquitin, which is not regulated by Myc oncoproteins. Standard error bars are provided for each cell line. B, Western blot analysis of MYCN, p21Cip1, p27Kip1, p53, and Actin in human neuroblastoma cell lines SK-N-MC, SK-N-SH, IMR-32, and CHP-134 either mock-treated or DFMO-treated for 72 hr.
Figure 5
Neuroblastomas that develop in DFMO-treated TH-MYCN mice have elevated levels of p21Cip1. A, Western blot analysis of MYCN, ODC, p21Cip1, p27Kip1, and tubulin levels in individual neuroblastoma arising in untreated or DFMO-treated TH-MYCN transgenic mice. B, qRT-PCR analysis comparing the levels of MYCN, ODC, p21Cip1, and p27Kip1 mRNAs in neuroblastoma that arose in either untreated (H2O) or DFMO-treated TH-MYCN transgenic mice. The relative expression in individual tumor samples is indicated by the individual marks (circle for untreated; squares for DFMO-treated) on the scatter blot and the average relative expression for the group is indicated by the bar. The average relative expression level of each gene is set at 1.0 for the untreated group and levels of mRNA are standardized to the expression of ubiquitin, which is not regulated by N-Myc. qRT-PCR analysis shows the expression of other genes in the polyamine pathway was unaffected in the DFMO-treated cohort of neuroblastoma (Supplementary Fig. S6).
Similar articles
- ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Buxton A, Gilmour SK, Marshall GM, Haber M. Hogarty MD, et al. Cancer Res. 2008 Dec 1;68(23):9735-45. doi: 10.1158/0008-5472.CAN-07-6866. Cancer Res. 2008. PMID: 19047152 Free PMC article. - Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ, Gamper I, Thorne M, Feith DJ, Takasaki KY, Wilson SM, Seki JA, Pegg AE, Byus CV, Bachmann AS. Wallick CJ, et al. Oncogene. 2005 Aug 25;24(36):5606-18. doi: 10.1038/sj.onc.1208808. Oncogene. 2005. PMID: 16007177 - DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS. Koomoa DL, et al. Int J Oncol. 2013 Apr;42(4):1219-28. doi: 10.3892/ijo.2013.1835. Epub 2013 Feb 21. Int J Oncol. 2013. PMID: 23440295 Free PMC article. - Polyamine synthesis as a target of MYC oncogenes.
Bachmann AS, Geerts D. Bachmann AS, et al. J Biol Chem. 2018 Nov 30;293(48):18757-18769. doi: 10.1074/jbc.TM118.003336. Epub 2018 Nov 7. J Biol Chem. 2018. PMID: 30404920 Free PMC article. Review. - The MYCN oncoprotein as a drug development target.
Lu X, Pearson A, Lunec J. Lu X, et al. Cancer Lett. 2003 Jul 18;197(1-2):125-30. doi: 10.1016/s0304-3835(03)00096-x. Cancer Lett. 2003. PMID: 12880971 Review.
Cited by
- miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A. Swarbrick A, et al. Nat Med. 2010 Oct;16(10):1134-40. doi: 10.1038/nm.2227. Epub 2010 Sep 26. Nat Med. 2010. PMID: 20871609 Free PMC article. - CDC27-ODC1 Axis Promotes Metastasis, Accelerates Ferroptosis and Predicts Poor Prognosis in Neuroblastoma.
Qiu L, Zhou R, Luo Z, Wu J, Jiang H. Qiu L, et al. Front Oncol. 2022 Feb 15;12:774458. doi: 10.3389/fonc.2022.774458. eCollection 2022. Front Oncol. 2022. PMID: 35242701 Free PMC article. - The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.
Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS. Geerts D, et al. Int J Cancer. 2010 May 1;126(9):2012-24. doi: 10.1002/ijc.25074. Int J Cancer. 2010. PMID: 19960435 Free PMC article. - Targeting RNA polymerase I to treat MYC-driven cancer.
Poortinga G, Quinn LM, Hannan RD. Poortinga G, et al. Oncogene. 2015 Jan 22;34(4):403-12. doi: 10.1038/onc.2014.13. Epub 2014 Mar 10. Oncogene. 2015. PMID: 24608428 Review. - Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer.
Olsen RR, Zetter BR. Olsen RR, et al. Mol Cancer Res. 2011 Oct;9(10):1285-93. doi: 10.1158/1541-7786.MCR-11-0178. Epub 2011 Aug 17. Mol Cancer Res. 2011. PMID: 21849468 Free PMC article. Review.
References
- Ries LAG, S M, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995. National Cancer Institute, SEER Program; 1999.
- De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol. 2003;21:1592–601. - PubMed
- Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. The N Engl J Med. 1985;313:1111–6. - PubMed
- Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–4. - PubMed
- Lee LA, Dang CV. Myc target transcriptomes. Curr Top Microbiol Immunol. 2006;302:145–67. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01-CA100603/CA/NCI NIH HHS/United States
- F32 CA115075-04/CA/NCI NIH HHS/United States
- R01 CA100603-06/CA/NCI NIH HHS/United States
- F32-CA115075/CA/NCI NIH HHS/United States
- R01 CA100603/CA/NCI NIH HHS/United States
- F32 CA115075/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous